Nextage Therapeutics Stock Probability Of Bankruptcy
| NXTG Stock | ILA 77.60 2.30 3.05% |
Nextage |
Nextage Therapeutics Company chance of distress Analysis
Nextage Therapeutics' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Nextage Therapeutics Probability Of Bankruptcy | Less than 26% |
Most of Nextage Therapeutics' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nextage Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Nextage Therapeutics probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Nextage Therapeutics odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Nextage Therapeutics financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Nextage Therapeutics has a Probability Of Bankruptcy of 26.0%. This is 39.94% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The probability of bankruptcy for all Israel stocks is 34.72% higher than that of the company.
Nextage Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nextage Therapeutics' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nextage Therapeutics could also be used in its relative valuation, which is a method of valuing Nextage Therapeutics by comparing valuation metrics of similar companies.Nextage Therapeutics is currently under evaluation in probability of bankruptcy category among its peers.
Nextage Fundamentals
| Return On Equity | -2.49 | |||
| Return On Asset | -0.79 | |||
| Operating Margin | 146.35 % | |||
| Current Valuation | 13.43 M | |||
| Shares Outstanding | 26.14 M | |||
| Shares Owned By Insiders | 82.36 % | |||
| Price To Book | 9.68 X | |||
| Price To Sales | 289.01 X | |||
| Revenue | 91 K | |||
| Gross Profit | 16 K | |||
| EBITDA | (7.58 M) | |||
| Net Income | (7.73 M) | |||
| Cash And Equivalents | 358 K | |||
| Cash Per Share | 0.16 X | |||
| Total Debt | 1.11 M | |||
| Current Ratio | 0.44 X | |||
| Book Value Per Share | 0.06 X | |||
| Cash Flow From Operations | (3.97 M) | |||
| Earnings Per Share | (0.30) X | |||
| Number Of Employees | 65 | |||
| Beta | 0.7 | |||
| Market Capitalization | 18.74 M | |||
| Total Asset | 4.27 M | |||
| Z Score | 6.3 | |||
| Net Asset | 4.27 M |
About Nextage Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nextage Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nextage Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nextage Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Nextage Stock
Nextage Therapeutics financial ratios help investors to determine whether Nextage Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nextage with respect to the benefits of owning Nextage Therapeutics security.